EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer

Inclusion Criteria: 1. Patients must be 18 years to 70 years; 2. Clinical diagnosis of EGFR positive for patients with metastatic colorectal cancer; 3. Patients must have a KPS of \>80, expected survival \> 3 months; 4. Patients must have at least one measurable lesions; 5. Recently did not use glucocorticoid; 6. Patients must have evidence of adequate hepatic and renal function as evidenced by the following laboratory parameters: WBC ≥ 3.0×109/L, Hb ≥90 g/L, PLT ≥100×109/L）; AST ≤2.5ULN，ALT ≤ 2.5ULN; Cr≤ 3ULN; TBIL≤ 3ULN， 7. Patients must have a good heart function (LVEF\>50%) ; 8. Patients must be willing to practice birth control during and for three months following treatment.NOTE:female participants of reproductive potential must have a negative serum pregnancy test, and willing to practice birth control during and for three months following treatment； 9. Patients must be willing to sign an informed consent. Exclusion Criteria: 1. Patients with other cancer history; 2. Patients allergic to cetuximab; 3. Patients with severe bronchitis, bronchial asthma, or severs pneumonia; 4. Patients with uncontrolled active infections (bacteria, viruses or fungi infection) ; 5. Patients with acute and chronic GVHD (graft versus host disease) 6. Patients with severe autoimmune diseases; 7. Previously treatment with T cell inhibitors (cyclophosphamide, FK506); 8. Patients with active hepatitis B or hepatitis C infection, HIV infection, syphilis serology reaction positive; 9. Patients who are participating or participated any other clinical research in the past 1 months; 10. Pregnant and/or lactating women will be excluded; -